NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-21

Study Completion Date

2021-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug. Eligible subjects will receive treatment for 28 days and be observed by a study doctor for approximately 56 days. Subjects will be randomly assigned to 1 of 4 treatment groups. 3 of the treatment groups will receive a specific dose NFX-179, and 1 group will receive placebo. The subject, study doctor, and NFlection Therapeutics will not know what treatment group each subject is assigned. Study participation requires at least 7 clinic visits, blood, urine, and tissue collection, images of the treated cutaneous neurofibromas, electrocardiograms, and information regarding the subject's medical and disease history.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845

Cutaneous Neurofibroma Neurofibromatosis 1

COMPLETED PHASE2

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

NCT00865644

Neurofibromatosis Type 1 Cutaneous Neurofibromas

COMPLETED PHASE1

HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy

NCT05119582

Cutaneous Neurofibroma

COMPLETED NA

Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger

NCT03381846

Dermatofibrosarcoma Protuberans

COMPLETED NA

CellFX System for the Treatment of Cutaneous Non-Genital Warts

NCT04554394

Warts Warts Hand Verruca

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurofibromatosis 1 Cutaneous Neurofibroma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NFX-179 Gel Low

NFX-179 Gel for topical administration, once daily for 28 days

Group Type EXPERIMENTAL

NFX-179 Gel

Intervention Type DRUG

gel for topical administration

NFX-179 Gel Mid

NFX-179 Gel for topical administration, once daily for 28 days

Group Type EXPERIMENTAL

NFX-179 Gel

Intervention Type DRUG

gel for topical administration

NFX-179 Gel High

NFX-179 Gel for topical administration, once daily for 28 days

Group Type EXPERIMENTAL

NFX-179 Gel

Intervention Type DRUG

gel for topical administration

Vehicle Arm

Vehicle Gel, for topical administration, once daily for 28 days

Group Type PLACEBO_COMPARATOR

Vehicle Gel

Intervention Type DRUG

vehicle gel for topical administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NFX-179 Gel

gel for topical administration

Intervention Type DRUG

Vehicle Gel

vehicle gel for topical administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is at least 18 years of age
2. Subject must provide written informed consent prior to any study procedures
3. Subject must have a clinical diagnosis of NF1
4. Subject has 6 Study cNF Tumors (5 Target cNF Tumors \[1 on the face; 4 on the anterior trunk or upper extremities\] that will be treated with the assigned study medication;1 Untreated cNF Tumor on the anterior trunk or upper extremities) that each meet the following criteria:

* Has, in the investigator's opinion, a clinically typical appearance
* Is dome shaped
* Is not pedunculated
* Is a discrete tumor
* Is not irritated
* Is not in an area subject to repeated trauma (e.g., area that is shaved, on the beltline, under a bra strap, etc.)
* Does not have an active cutaneous infection
* Has a diameter that is ≥5mm and ≤10mm
* Has a height of ≥2mm
* Is, when centered in the center of the provided template, the only cNF tumor visible
* Is not within 5mm of the orbital rim.
5. Subject is willing to have the 5 Target cNF Tumors and the 1 Untreated cNF Tumor excised at the end of the treatment period
6. Subject is willing to have hair in the area surrounding the Target cNF Tumors shaved, if necessary, to obtain photographs
7. Subject is willing to minimize exposure of each Target cNF to natural and artificial ultraviolet radiation
8. Subject is willing to forego treatment of the Target cNF Tumors, except protocol specified therapy, during the study
9. Female subjects who are women of childbearing potential must have a negative urine pregnancy test result and be willing to use a protocol approved, contraceptive method for the duration of the study
10. Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria

1. Subject has applied any of the following topical products in the previous 30 days on or in proximity to any Study cNF Tumor that, in the investigator's opinion, impairs evaluation of any the tumor or which exposes the subject to an unacceptable risk by study participation:

* Corticosteroids
* Retinoids (e.g., tazarotene, tretinoin, adapalene)
* \> 5% of an alpha-hydroxy acid (e.g., glycolic acid, lactic acid)
* Fluorouracil
* Imiquimod
2. Any Study cNF Tumor has ever been treated with an MEK inhibitor or a BRAF inhibitor
3. The subject has used any of the following systemic medications in the noted time period:

* Retinoids (e.g., etretinate, isotretinoin) within the previous 90 days
* MEK inhibitors within the previous 180 days
* BRAF inhibitors within the previous 180 days
4. Subject has a history of hypersensitivity to any of the ingredients in the study medications
5. Subject has any known intercurrent illness or physical condition that would, in the investigator's opinion, impair evaluation of a Target cNF Tumor or which exposes the subject to an unacceptable risk by study participation
6. Subject has, in the investigator's opinion, clinically relevant history of liver disease, including viral hepatitis, current alcohol abuse, or cirrhosis
7. Subject has a history of metastatic disease, or active cancer (excluding nonmelanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or Stage 0 chronic lymphocytic lymphoma) within the previous 5 years
8. Subject has any condition (e.g., other skin conditions or diseases, metabolic dysfunction, physical examination findings, clinical laboratory findings) or situation (e.g., vacation, scheduled surgery) that would, in the investigator's opinion, impair evaluation of a Target cNF Tumor or which exposes the subject to an unacceptable risk by study participation
9. Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within the previous 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No